SCHEMBL9243736

SCHEMBL9243736

Cc1cc(C)c(S(=O)(=O)O)c(C)c1.[Ag]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
MMP1 P03956 1/20 0.56
MMP2 P08253 1/20 0.56
MMP9 P14780 1/20 0.56
MMP8 P22894 1/20 0.56
MMP13 P45452 1/20 0.56
F2 P00734 3/20 0.50
PRSS1 P07477 3/20 0.50
PRSS2 P07478 3/20 0.50
PRSS3 P35030 3/20 0.50
RAPGEF4 Q8WZA2 6/20 0.48
GAA P10253 3/20 0.44
POLB P06746 1/20 0.44
TSHR P16473 1/20 0.44
GFER P55789 1/20 0.44
FABP4 P15090 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
CYTH2 Q99418 1/20 0.42
MAPT P10636 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL5999943 0.97 CA1 (0.58) CA1CA2MMP1MMP2MMP9
SCHEMBL7930818 0.97 CA1 (0.58) CA1CA2MMP1MMP2MMP9
SCHEMBL23788 0.97 CA1 (0.58) CA1CA2MMP1MMP2MMP9
SCHEMBL10846507 0.97 CA1 (0.58) CA1CA2MMP1MMP2MMP9
Water SCHEMBL458685 0.95 CA1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL2549047 0.95 CA1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL28656334 0.95 CA1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL28505545 0.95 CA1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL9165332 0.95 CA1 (0.56) CA1CA2MMP1MMP2MMP9
Hydrochloric Acid SCHEMBL943801 0.95 CA1 (0.56) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2663398-B1 Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE CALIFORNIA INST OF TECHN (US) 2018-07-18 EP disclosed
US-9597674-B2 Z-selective olefin metathesis catalysts and their synthetic procedure CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2017-03-21 US disclosed
US-20140106960-A1 Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2014-04-17 US disclosed
EP-2663398-A2 Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE California Institute of Technology (US) 2013-11-20 EP disclosed
WO-2012097379-A2 Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2012-07-19 WO disclosed
US-5424378-A Catalyzing in the presence of a mixture comprising an alkyl-sulfonate cyclopentadienyl titanium or zirconium compound and an aluminoxane MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1995-06-13 US disclosed
US-5412128-A Catalyst for olefin polymerization, process for the polymerization of olefin, and transition metal compound employable for the catalyst MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1995-05-02 US disclosed
US-5409874-A Containing transition metal compound having cyclopentadienyl skeleton and sulfonate group, aluminoxane or benzene insoluble organoaluminum compound MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1995-04-25 US disclosed
EP-0519746-A1 Catalyst for olefin polymerization, process for the polymerization of olefin, and transition metal compound employable for the catalyst MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1992-12-23 EP disclosed
US-4489091-A ESTERASE AND ANTIBODY INHIBITORS TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1984-12-18 US disclosed
US-4411911-A Method of treating hyperlipidemia and inflammation with sulfonate derivatives TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) 1983-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140106960-A1 Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE OPRM1, C1R, NPY2R CA1 537/4885CA2 1007/4885MMP1 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.